Literature DB >> 22405728

RNA-binding proteins in microsatellite expansion disorders: mediators of RNA toxicity.

Gloria V Echeverria1, Thomas A Cooper.   

Abstract

Although protein-mediated toxicity in neurological disease has been extensively characterized, RNA-mediated toxicity is an emerging mechanism of pathogenesis. In microsatellite expansion disorders, expansion of repeated sequences in noncoding regions gives rise to RNA that produces a toxic gain of function, while expansions in coding regions can disrupt protein function as well as produce toxic RNA. The toxic RNA typically aggregates into nuclear foci and contributes to disease pathogenesis. In many cases, toxicity of the RNA is caused by the disrupted functions of RNA-binding proteins. We will discuss evidence for RNA-mediated toxicity in microsatellite expansion disorders. Different microsatellite expansion disorders are linked with alterations in the same as well as disease-specific RNA-binding proteins. Recent studies have shown that microsatellite expansions can encode multiple repeat-containing toxic RNAs through bidirectional transcription and protein species through repeat-associated non-ATG translation. We will discuss approaches that have characterized the toxic contributions of these various factors.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22405728      PMCID: PMC3372679          DOI: 10.1016/j.brainres.2012.02.030

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  121 in total

1.  Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome.

Authors:  F Tassone; R J Hagerman; A K Taylor; L W Gane; T E Godfrey; P J Hagerman
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

2.  Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat.

Authors:  A Mankodi; E Logigian; L Callahan; C McClain; R White; D Henderson; M Krym; C A Thornton
Journal:  Science       Date:  2000-09-08       Impact factor: 47.728

3.  Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy.

Authors:  J W Miller; C R Urbinati; P Teng-Umnuay; M G Stenberg; B J Byrne; C A Thornton; M S Swanson
Journal:  EMBO J       Date:  2000-09-01       Impact factor: 11.598

4.  Mutant human embryonic stem cells reveal neurite and synapse formation defects in type 1 myotonic dystrophy.

Authors:  Antoine Marteyn; Yves Maury; Morgane M Gauthier; Camille Lecuyer; Remi Vernet; Jérôme A Denis; Geneviève Pietu; Marc Peschanski; Cécile Martinat
Journal:  Cell Stem Cell       Date:  2011-03-31       Impact factor: 24.633

5.  An antisense CAG repeat transcript at JPH3 locus mediates expanded polyglutamine protein toxicity in Huntington's disease-like 2 mice.

Authors:  Brian Wilburn; Dobrila D Rudnicki; Jing Zhao; Tara Murphy Weitz; Yin Cheng; Xiaofeng Gu; Erin Greiner; Chang Sin Park; Nan Wang; Bryce L Sopher; Albert R La Spada; Alex Osmand; Russell L Margolis; Yi E Sun; X William Yang
Journal:  Neuron       Date:  2011-05-12       Impact factor: 17.173

6.  Spinocerebellar ataxia type 8: clinical features in a large family.

Authors:  J W Day; L J Schut; M L Moseley; A C Durand; L P Ranum
Journal:  Neurology       Date:  2000-09-12       Impact factor: 9.910

7.  A family of human RNA-binding proteins related to the Drosophila Bruno translational regulator.

Authors:  P J Good; Q Chen; S J Warner; D C Herring
Journal:  J Biol Chem       Date:  2000-09-15       Impact factor: 5.157

8.  The SCA8 transcript is an antisense RNA to a brain-specific transcript encoding a novel actin-binding protein (KLHL1).

Authors:  J P Nemes; K A Benzow; M L Moseley; L P Ranum; M D Koob
Journal:  Hum Mol Genet       Date:  2000-06-12       Impact factor: 6.150

9.  Mis-splicing of Tau exon 10 in myotonic dystrophy type 1 is reproduced by overexpression of CELF2 but not by MBNL1 silencing.

Authors:  C M Dhaenens; H Tran; M-L Frandemiche; C Carpentier; S Schraen-Maschke; A Sistiaga; M Goicoechea; S Eddarkaoui; E Van Brussels; H Obriot; A Labudeck; M H Gevaert; F Fernandez-Gomez; N Charlet-Berguerand; V Deramecourt; C A Maurage; L Buée; A Lopez de Munain; B Sablonnière; M L Caillet-Boudin; N Sergeant
Journal:  Biochim Biophys Acta       Date:  2011-03-23

10.  Identification of MBNL1 and MBNL3 domains required for splicing activation and repression.

Authors:  Ioannis Grammatikakis; Young-Hwa Goo; Gloria V Echeverria; Thomas A Cooper
Journal:  Nucleic Acids Res       Date:  2010-11-24       Impact factor: 16.971

View more
  50 in total

Review 1.  Fragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms.

Authors:  Paul Hagerman
Journal:  Acta Neuropathol       Date:  2013-06-21       Impact factor: 17.088

Review 2.  Clinical neurogenetics: amyotrophic lateral sclerosis.

Authors:  Matthew B Harms; Robert H Baloh
Journal:  Neurol Clin       Date:  2013-11       Impact factor: 3.806

Review 3.  A census of human RNA-binding proteins.

Authors:  Stefanie Gerstberger; Markus Hafner; Thomas Tuschl
Journal:  Nat Rev Genet       Date:  2014-11-04       Impact factor: 53.242

Review 4.  Evolutionary conservation and expression of human RNA-binding proteins and their role in human genetic disease.

Authors:  Stefanie Gerstberger; Markus Hafner; Manuel Ascano; Thomas Tuschl
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

5.  Neurodegenerative diseases: G-quadruplex poses quadruple threat.

Authors:  J Paul Taylor
Journal:  Nature       Date:  2014-03-05       Impact factor: 49.962

Review 6.  Antisense oligonucleotide therapy for the treatment of C9ORF72 ALS/FTD diseases.

Authors:  Giulietta Riboldi; Chiara Zanetta; Michela Ranieri; Monica Nizzardo; Chiara Simone; Francesca Magri; Nereo Bresolin; Giacomo P Comi; Stefania Corti
Journal:  Mol Neurobiol       Date:  2014-05-09       Impact factor: 5.590

7.  Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3'UTR RNA.

Authors:  Ramesh S Yadava; Qing Yu; Mahua Mandal; Frank Rigo; C Frank Bennett; Mani S Mahadevan
Journal:  Hum Mol Genet       Date:  2020-06-03       Impact factor: 6.150

8.  A novel CUG(exp)·MBNL1 inhibitor with therapeutic potential for myotonic dystrophy type 1.

Authors:  Amin Haghighat Jahromi; Lien Nguyen; Yuan Fu; Kali A Miller; Anne M Baranger; Steven C Zimmerman
Journal:  ACS Chem Biol       Date:  2013-03-20       Impact factor: 5.100

9.  MBNL Sequestration by Toxic RNAs and RNA Misprocessing in the Myotonic Dystrophy Brain.

Authors:  Marianne Goodwin; Apoorva Mohan; Ranjan Batra; Kuang-Yung Lee; Konstantinos Charizanis; Francisco José Fernández Gómez; Sabiha Eddarkaoui; Nicolas Sergeant; Luc Buée; Takashi Kimura; H Brent Clark; Joline Dalton; Kenji Takamura; Sebastien M Weyn-Vanhentenryck; Chaolin Zhang; Tammy Reid; Laura P W Ranum; John W Day; Maurice S Swanson
Journal:  Cell Rep       Date:  2015-08-06       Impact factor: 9.423

Review 10.  Fragile X-associated tremor/ataxia syndrome - features, mechanisms and management.

Authors:  Randi J Hagerman; Paul Hagerman
Journal:  Nat Rev Neurol       Date:  2016-06-24       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.